Among patients hospitalized with COVID-19, myocardial injury as determined by high-sensitivity cardiac troponin T was closely linked to mortality or long term  COVID-19 symptoms, says a new prospective study.  The study, conducted by a team led by Dr Brittany Weber, a cardiologist at Brigham and Women’s Hospital and instructor in medicine at Harvard Medical School, analysed 483 patients (median age, 63 years; 51% women) who were admitted to the hospital for COVID-19 and had high-sensitivity cardiac troponin T measured at admission from March to May 2020. The researchers observed that during the index hospitalization, 18.8 percent of patients died, 14.4 percent had thrombotic complications and 25.6 percent had cardiovascular complications. More importantly, the researchers found about 22.2 percent of the patients who survived during hospitalisation died  at 1 year. The study, published in the Journal of American Heart Association, also observe that after adjustment for age, sex, CAD, hypertension, hyperlipidemia, HF and diabetes, cardiac injury was associated with elevated risk for mortality compared with undetectable troponin (HR = 13.76; 95% CI, 1.85-102.3; P = .01), but there was no difference in mortality risk between low-level positive troponin and undetectable troponin (HR = 2.31; 95% CI, 0.27-19.48; P = .44).